Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Short-term Investments: 2015-2024

Historic Short-term Investments for ImmunityBio (IBRX) over the last 10 years, with Dec 2024 value amounting to $6.4 million.

  • ImmunityBio's Short-term Investments rose 973.70% to $197.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $197.6 million, marking a year-over-year increase of 973.70%. This contributed to the annual value of $6.4 million for FY2024, which is 532.41% up from last year.
  • As of FY2024, ImmunityBio's Short-term Investments stood at $6.4 million, which was up 532.41% from $1.0 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Short-term Investments registered a high of $136.0 million during FY2021, and its lowest value of $1.0 million during FY2023.
  • Its 3-year average for Short-term Investments is $3.3 million, with a median of $2.5 million in 2022.
  • As far as peak fluctuations go, ImmunityBio's Short-term Investments tumbled by 98.13% in 2022, and later soared by 532.41% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's Short-term Investments stood at $61.1 million in 2020, then spiked by 122.44% to $136.0 million in 2021, then plummeted by 98.13% to $2.5 million in 2022, then plummeted by 60.32% to $1.0 million in 2023, then spiked by 532.41% to $6.4 million in 2024.